COVID-19 vaccination rates lower in cancer patients with comorbidities, some cancer types, and social factors

Ousted CDC director testifies before Senate HELP Committee

Ousted from her position as director of the Centers for Disease Control and Prevention less than a month after her confirmation, Susan Monarez has now had the chance to tell her side of the story before Congress.

September 19, 2025

Vol.51 No.34

By Claire Marie Porter

Cancer Policy

CDC’s ACIP makes changes to childhood vaccine recommendations in first meeting since Monarez’s ouster

At a two-day meeting, the Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted 8-3 to change the current recommendations that allow children under age 4 to receive the MMRV vaccine, a combination shot for measles, mumps, rubella and chickenpox (or varicella).

September 19, 2025

Vol.51 No.34

By Claire Marie Porter

Clinical Roundup

Checkpoint therapy breakthrough sparks new vaccine

Immune-checkpoint therapy, which attempts to harness a patient’s own immune system to fight cancer, has revolutionized cancer care over the past two decades.

September 12, 2025

Vol.51 No.33

Capitol Hill

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.

September 05, 2025

Vol.51 No.32

By Claire Marie Porter

Cancer Policy

The departure (and return) of Vinay Prasad

At the end of July, after just a few months as director of the Center for Biologics Evaluation and Research, Vinay Prasad resigned.

September 05, 2025

Vol.51 No.32

By Claire Marie Porter

Clinical Roundup

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

ELI-002 2P, an off-the-shelf cancer vaccine, can trigger powerful and lasting immune responses, and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations, according to a study published in Nature Medicine.

September 05, 2025

Vol.51 No.32

COVID-19 vaccination rates lower in cancer patients with comorbidities, some cancer types, and social factors

YOU MAY BE INTERESTED IN

Ousted CDC director testifies before Senate HELP Committee

CDC’s ACIP makes changes to childhood vaccine recommendations in first meeting since Monarez’s ouster

Checkpoint therapy breakthrough sparks new vaccine

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

The departure (and return) of Vinay Prasad

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

Renew today!

Subscriber content

Never miss an issue!

Login

COVID-19 vaccination rates lower in cancer patients with comorbidities, some cancer types, and social factors

YOU MAY BE INTERESTED IN

Ousted CDC director testifies before Senate HELP Committee

CDC’s ACIP makes changes to childhood vaccine recommendations in first meeting since Monarez’s ouster

Checkpoint therapy breakthrough sparks new vaccine

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearingKennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

The departure (and return) of Vinay Prasad

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

Never miss an issue!

Login

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”